HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Chattem CFO Bosworth To Succeed Taylor As President

This article was originally published in The Rose Sheet

Executive Summary

Chattem board member and former exec Robert Bosworth will succeed Alec Taylor as president and chief operating officer, effective Sept. 19

You may also be interested in...



Selsun Salon Could Garner Up To $17 Mil. In Annual Sales – Chattem

Selsun Salon hair care is expected to generate $12 mil.-$17 mil. in retail sales annually, according to Chattem. The range is likely to contribute $1 mil. to the firm's top line in Q4, the company said

Selsun Salon Could Garner Up To $17 Mil. In Annual Sales – Chattem

Selsun Salon hair care is expected to generate $12 mil.-$17 mil. in retail sales annually, according to Chattem. The range is likely to contribute $1 mil. to the firm's top line in Q4, the company said

Chattem Q2

Chattem will begin shipping Selsun Salon dandruff shampoo Nov. 1, the firm announces June 16. The new line "combines maximum strength dandruff control with a salon quality shampoo" and will be offered in four formulas: classic, moisturizing, volumizing and a 2-in-1 shampoo plus conditioner; COO Alec Taylor said the line will be a "big addition" with upside comparable to the firm's Icy Hot topical extensions. Chattem's sales increased 15% to $75.7 mil. while net earnings more than doubled to $15.5 mil. in Q2 (ended May 31). The firm attributed the strong results in part to 38% growth in the topical analgesic franchise due to strong sales of Aspercreme, Capzasin and Icy Hot...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel